Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. - Wikidata - wikimedia - TriplyDB

Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase.

Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase.

http://www.wikidata.org/entity/Q44626758

about

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential Comparison of the properties of the five soluble guanylyl cyclase subunits in Drosophila melanogaster.Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS Hemoglobin-mediated nitric oxide signaling NO and CO differentially activate soluble guanylyl cyclase via a heme pivot-bend mechanism.Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase.Crystal structure of the Alpha subunit PAS domain from soluble guanylyl cyclase Insights into Soluble Guanylyl Cyclase Activation Derived from Improved Heme-Mimetics Identification of residues in the heme domain of soluble guanylyl cyclase that are important for basal and stimulated catalytic activity Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.Multiple lineage specific expansions within the guanylyl cyclase gene family Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion.The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Oxidation and loss of heme in soluble guanylyl cyclase from Manduca sexta.Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.Cobinamides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain.Aspartate 102 in the heme domain of soluble guanylyl cyclase has a key role in NO activation.Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice.Primary response of the sGC heme binding domain to the cleavage of the Fe-His bond.Protoporphyrin IX/Cobyrinate Derived Hybrids - Novel Activators of Soluble Guanylyl Cyclase Cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of hypothetical protein SCO4226 from Streptomyces coelicolor A3(2).Concepts of neural nitric oxide-mediated transmission.Heme deficiency of soluble guanylate cyclase induces gastroparesis.Modulation of cGMP in heart failure: a new therapeutic paradigm.Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases.YC-1 binding to the β subunit of soluble guanylyl cyclase overcomes allosteric inhibition by the α subunit.Vascular dysfunction in cerebrovascular disease: mechanisms and therapeutic intervention.A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.Guanylate cyclase activators, cell volume changes and IOP reduction.Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction.The chemistry and biology of soluble guanylate cyclase stimulators and activators.Nitric oxide-sensing H-NOX proteins govern bacterial communal behavior.NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy.Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?

P2860

Q24656131-D6675FA0-426B-47D7-8D61-49D8E7BC6D77 Q24815038-09B848F5-AB2F-4040-9AF3-0F3E7359DEA0 Q27021649-D6C05707-9B48-4BC2-A924-338F674EC870 Q27022432-402E9B66-8525-4024-8678-80C2680921C1 Q27641107-1F585A1A-1764-40E4-985D-F7F3980B5C0F Q27661554-03E3EDAF-37B0-4EFF-A4CD-6D2BA70F2E54 Q27679506-8BC11996-9675-4D22-A91D-ABBEAB06707E Q27680135-C3C25448-22DE-4FB6-88DD-96A79DC860E2 Q28477878-CB377B1B-61E0-4D6C-AAA7-CEEC9EC972C3 Q28741339-2D8CE405-69F7-481C-B776-45BA6C05D315 Q30315850-23DB5329-3D74-4357-B86E-1446FF6F4DF9 Q33237078-7F9EE047-BC08-4AB8-966A-8EF44E7F50F0 Q33957600-81BF1E32-8E88-4BCB-A3AC-359ED5E46142 Q34042836-F03927A8-168D-416C-9A98-A86CC6AC8EA8 Q34538482-A1F4BD05-2835-425E-B4F6-D2A0FBDAA5D5 Q35009484-49CFDE8D-AA5E-4719-AB0E-6D16F12E7454 Q35075847-5FD755FE-347C-497A-9635-7380B3C1C6D2 Q35083181-E8E1730A-51DA-4EA4-9D8F-788CDB11E1C4 Q35543584-E1FF33F3-4E9C-42F9-8FEA-D7D3AA06128D Q35776824-04E05260-CBDB-4B4E-BCD7-1DBCB9B4C818 Q35855521-DE9D9FB6-E4D7-4CA8-88AA-3F258FDD21B6 Q36424922-73E992EA-BEE8-4BFB-88DF-96E249C28F61 Q36641270-47C0F39C-0CD9-4DFD-859C-F65364131FDD Q36693586-184BEF5A-FD07-42E8-AE0E-264CC4943DE0 Q36865969-D8A5F241-761C-40CF-B795-697D84CF39AF Q37029494-1A064A41-F9D7-42DA-A6DF-F41E914BF408 Q37064834-5A3AFD73-7CC6-4AE5-BFD7-B2EDF363BBE0 Q37329891-1809CBF5-F0D1-44E5-9D53-C55FA2562800 Q37343908-BFC40C12-3521-4A8D-81CA-A232C7EF880C Q37511692-7B7002B3-7BEF-437E-B676-5E6D200F013B Q37557818-35C7E28D-E221-4CDB-B79A-A008978D4910 Q37725077-64B5E5A4-B7E3-4237-A660-786B9AF09724 Q37820206-A3D566CA-69A0-4792-B341-9589A2A036E9 Q37969557-6336A88E-7309-4352-BC36-EF67F7C77BBA Q38000562-4A912259-8214-41E0-878D-56A9C3EA723E Q38118626-F3F9D22F-BD80-4457-B73C-ECE5EA1334EE Q38130465-17D5B49D-F7EE-46D6-AFB0-04167AC38E79 Q38151386-05F4505B-57E5-4BC9-877D-BD4ABB6871B2 Q38758203-80BD0834-CC93-479B-84B8-C749F139540E Q38818645-BD32691C-5483-4858-ADA1-D589D7E89959

P2860

Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase.

http://www.wikidata.org/entity/Q44626758

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Identification of residues cru ...... of soluble guanylate cyclase.

@en

Identification of residues cru ...... of soluble guanylate cyclase.

@nl

type

label

Identification of residues cru ...... of soluble guanylate cyclase.

@en

Identification of residues cru ...... of soluble guanylate cyclase.

@nl

prefLabel

Identification of residues cru ...... of soluble guanylate cyclase.

@en

Identification of residues cru ...... of soluble guanylate cyclase.

@nl

P1433

Q44626758-F6A70083-8B40-44C4-BB34-A4B702EF597A

P1476

Q44626758-9408C54F-C296-46E4-A5F9-5EE3C9A3CA75

P2093

Q44626758-39B2C217-0769-41AF-B7CB-09C7579DDFC0

Q44626758-6762CE54-1FF7-4335-BA87-42A5799B8A18

Q44626758-8B05B6B7-28F3-4FAD-9011-50E6F3F75930

Q44626758-DB7EE19B-2129-4AC1-A8BF-96E48E09F7C2

P2860

Q44626758-0220AE67-7A00-4AED-A3B7-28C5D51B4E8E

Q44626758-0EB853F8-D780-4CE3-BD72-AA91C8BC1CF9

Q44626758-0FD6E073-C6E4-4C61-B9C8-C9BCC6A9C434

Q44626758-1A9DCCE2-210C-405F-829C-508DEC3A6D55

Q44626758-2DB15570-0387-40B2-80D0-52A6D1962DE3

Q44626758-31654C8F-7971-4D72-BB0E-34E5055DBE90

Q44626758-35506388-7051-4B03-8AF2-2883FE0D55F9

Q44626758-3F8B6CB0-F302-4C03-B79A-F64B73908565

Q44626758-47B34208-9D1A-42EB-B76F-A1713CA3042B

Q44626758-501C998E-537A-4FF4-AEEF-24256D43CBFD

P304

Q44626758-8E1D1491-43BA-4068-8653-E8A3D8BF603C

P31

Q44626758-1A5483A2-7387-48B4-93E0-D7501078B32B

P356

Q44626758-5A786BB4-D1F3-4C26-9EBE-CF1E8CBE865D

P407

Q44626758-D94F298F-EC2B-4D06-B30F-FAAABCFC1D4A

P433

Q44626758-15104827-8E03-41DD-9507-66A9A1A6B1D6

P478

Q44626758-721AF800-ADC5-4310-9210-FC1FCCC1B095

P50

Q44626758-EEED016B-F85D-4229-88D8-6B39FE84ECE6

P577

Q44626758-317EAC4A-188A-40C1-9CC8-4EDD8A656E48

P698

Q44626758-0F1662EE-66C7-483F-97FF-D02DDA21500B

P356

P1433

Journal of Biological Chemistry

P1476

Identification of residues cru ...... of soluble guanylate cyclase.

@en

P2093

Frank Wunder

http://www.w3.org/2001/XMLSchema#string

Henning Schröder

http://www.w3.org/2001/XMLSchema#string

Matthias Schramm

http://www.w3.org/2001/XMLSchema#string

Peter M Schmidt

http://www.w3.org/2001/XMLSchema#string

P2860

Ancient conserved domains shared by animal soluble guanylyl cyclases and bacterial signaling proteins

New mechanistic insights from structural studies of the oxygen-sensing domain of Bradyrhizobium japonicum FixL

Resonance raman characterization of the heme domain of soluble guanylate cyclase.

NO-independent regulatory site on soluble guanylate cyclase.

Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants?

YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components

Nitric oxide donor drugs: current status and future trends.

Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies

NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.

Nitric oxide-releasing drugs.

P304

3025-3032

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M310141200

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

279

http://www.w3.org/2001/XMLSchema#string

P50

Johannes-Peter Stasch

P577

2003-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14570894

http://www.w3.org/2001/XMLSchema#string